TAG:
emr
Meaningful Use Stage 2 Is Problem for EHR Firms
By Joseph Burns | From the Volume XXII No. 2 – January 26, 2015 Issue
CEO SUMMARY: EHR system vendors must now comply with the federal government’s Meaningful Use Stage 2 requirements. Well-established EHR vendors will survive. But smaller EHR companies may struggle to provide the enhancements to their first generation EHR products that are require…
Public Comment Started on FDA LDT Regulations
By Joseph Burns | From the Volume XXI No. 15 – November 3, 2014 Issue
CEO SUMMARY: On October 3, the FDA published draft guidelines to regulate laboratory-developed tests (LDTs). Pathologists and lab executives now have 120 days to comment on the guidelines. Several prominent national lab associations have expressed concerns about this additional bureaucrat…
Florida Ob-Gyns Call for UHC to End BeaconLBS
By Joseph Burns | From the Volume XXI No. 15 – November 3, 2014 Issue
CEO SUMMARY: In Florida, obstetricians and gynecologists are complaining about the burdensome nature of the new lab test management system introduced by UnitedHealthcare. In addition to calling for an end to the program, some ob-gyns plan not to use the system, a process that could lead U…
UnitedHealth Answers Queries about Function of BeaconLBS
By Robert Michel | From the Volume XXI No. 15 – November 3, 2014 Issue
ANSWERS TO QUESTIONS SUBMITTED to UnitedHealthcare about the insurer’s laboratory benefit management program now coming into operation in Florida were provided by the company’s public communication officer. These answers are reproduced below: Q: Will BeaconLBS proces…
Partners Consolidates AP Using Common IT System
By Joseph Burns | From the Volume XXI No. 9 – June 30, 2014 Issue
CEO SUMMARY: Partners HealthCare of Boston, Massachusetts, is creating a single informatics platform for CP and AP across all six of the hospitals that it operates. It will replace 19 different pathology systems currently used at six sites with just seven integrated pathology systems. As …
Meaningful Use Stage 2 to Challenge Labs in 2014
By Joseph Burns | From the Volume XX, No. 17 – December 23, 2013 Issue
CEO SUMMARY: On December 6, the Centers for Medicare & Medicaid Services proposed to delay implementation of Meaningful Use (MU) Stage 2 until 2016. One reason is that only about 80 vendors have certified their products to MU Stage 2. That is a small proportion of the almost 900 vendo…
Portland Lab Leverages Informatics for Growth
By Joseph Burns | From the Volume XX No.14 – October 21, 2013 Issue
CEO SUMMARY: In Portland, Oregon, Legacy Laboratory Services, a division of Legacy Health, continues to post strong volume growth. One driver supporting this growth is the lab’s ability to implement connections between its laboratory information system (LIS) and the electronic …
Memorial Hermann’s Health Info Exchange Helps Lab Outreach
By Joseph Burns | From the Volume XIX No. 16 – November 19, 2012 Issue
CEO SUMMARY: In Houston, Memorial Hermann Healthcare System has put together a health information exchange (HIE) to serve the Houston market. By design, this HIE not only gives physicians immediate access to a wide variety of patient data, but also supports the type of workflow required f…
Louisiana Pathologists ‘Moonlight’ as Consultants
By Joseph Burns | From the Volume XIX No. 15 – October 29, 2012 Issue
CEO SUMMARY: Few independent pathology groups have developed robust laboratory consulting businesses. But adopting that strategy has brought important benefits to Delta Pathology Group, LLC, of Shreveport, Louisiana. Not only has providing lab consulting services to cash-strapped hospital…
Narrower Provider Networks Topic during Quest Conference Call
By Robert Michel | From the Volume XIX No. 12 – August 27, 2012 Issue
SINCE MAY 1, 2012, the nation’s largest clinical laboratory company has had a new CEO, who is Stephen H. Rusckowski. The company’s second quarter conference call provided an opportunity to learn more about how he views Quest Diagnostics Incorporated. Conducted on July 19, the fi…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized